Therapeutic efficacy of intralesional bleomycin injection for laryngopharyngeal haemangioma in adults

Abstract

Background: Head and neck haemangiomas in the pharynx and larynx are rare, and the injection of bleomycin is currently one of the effective treatments. However, data on the therapeutic efficacy of this treatment are scarce.

Objectives: To evaluate the clinical efficacy of bleomycin injection in the treatment of laryngopharyngeal haemangioma in adults and determine factors affecting efficacy.

Materials and Methods: The clinical data of 42 adult patients with laryngopharyngeal haemangioma treated by intralesional bleomycin injection were retrospectively analysed to evaluate the clinical efficacy. Two groups (haemangioma reduction <50% and haemangioma reduction ≥50%) were compared to analyse factors affecting efficacy.

Results: Seventy-five injections were administered to 42 patients: 34 (34/42 81%) patients with a haemangioma reduction ≥50% and 8 (8/42 19%) with a haemangioma reduction <50%. There was no difference in age, sex, haemangioma shape or number of operations between the two groups, but there was a significant difference in the base area of the haemangioma.

Conclusions and Significance: Intralesional bleomycin injection is effective for the treatment of laryngopharyngeal haemangioma in adults. The base area of the haemangioma affects the therapeutic efficacy.

Chinese abstract

背景：咽部和喉部的头颈部血管瘤很少见。注射博来霉素(Bleomycin)是目前有效的治疗方法之一。然而, 关于这种治疗的疗效的数据很少。

目的：评价博莱霉素注射液治疗成人喉咽血管瘤的临床疗效, 并确定影响疗效的因素。

材料与方法：回顾性分析42例经病灶内注射博莱霉素治疗的喉咽血管瘤患者的临床资料, 评价临床疗效。比较两组（血管瘤减少<50％和血管瘤减少≥50％）以分析影响疗效的因素。

结果：对42例患者给予75次注射。结果34例患者（34/42 81％）血肿减少≥50％和8例（8/42 19％）血肿减少<50％。两组之间在年龄、性别、血管瘤形状或手术次数方面无差异, 但在血管瘤的基部面积上有显著差异。

结论与意义：病灶内注射博来霉素可有效治疗成人喉咽血管瘤。血管瘤的基部面积影响治疗效果。

Keywords:

• Bleomycin
• injection
• pharynx
• larynx
• haemangioma

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Additional information

Funding

This study was supported by Beijing Natural Science Foundation [Grand Number 7182036], and National Key Research and Development Program of China [Grant Number 2017YFC0112500].